Assessing Cognitive Impairment in People with Dementia Associated Disorders: Self‐Reported Recognitive Impairment Contrasted with Computerized Multi‐Domain Cognitive Testing – Truth be Told

Dementia associated diseases (DAD) are characterized by progressive impairment of cognition that interferes with an individual’s ability to function independently. Clinically, cognitive impairment (CI) can vary in degree and combination across multiple cognitive domains (CD). Clinician and patient with DAD (PwDAD) recognition of such varied types/degrees of CI might not only be sub‐optimal, but also unable to recognize subtle change and progression. Patient self‐reported outcome measures (PRO) are used to gauge CI or disability progression. Traditional measures (MOCA, MMSE) include a dichotomous outcome measure and routine neuropsychological screening might not be practical. Quantitative and objective screening across multiple CD can be accomplished in routine care with validated, examiner independent, computerized multi‐domain cognitive assessment battery (CAB‐NT, NeuroTrax). NeuroQOL Cognitive Function Short‐Form (CF‐SF) is one validated disease agnostic PRO that can be incorporated to evaluate patient perception of disease impact and change on CI. The relationship of CF‐SF to multi‐domain quantitative CAB has not been explored in PwDAD.